美国 · 股市与财经 · MarketWatch
Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays
Novo Nordisk received notice from the Food and Drug Administration that its review of denecimig for the treatment of hemophilia A is still ongoing. The FDA hasn't communicated a…
在 MarketWatch 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.marketwatch.com)
